Drug intelligence / Profile preview

ARBM-301

Development stage: Preclinical
Lead developer: Arbormed
Modality: Small Molecules
Administration: Intrapleural (preclinical Studies)

Overview

ARBM-301 is a novel small molecule drug under development by ArborMed for the treatment of pendred syndrome, specifically targeting sensorineural hearing loss. Its mechanism of action involves modulation of anion transport proteins, which are implicated in the pathophysiology of pendred syndrome. As a new molecular entity, it represents a first-in-class approach to address this rare genetic disorder that leads to progressive hearing loss[1].

Brand names: ARBM-301ARBM301ARBM 301
Other names: ARBM 301ARBM301ARBM-301

Targets

AE1 (Anion exchange protein 1)

Beyond the preview

Go deeper on ARBM-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARBM-301.

Explore the full profile